Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Revenue projections:

Revenue projections for RMD
Revenue projections for RMD

Revenues for RMD are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 3.060000
forwardPE 17.936157
debtToEquity 13.411000
earningsGrowth 0.145000
revenueGrowth 0.110000
grossMargins 0.614740
operatingMargins 0.351630
trailingEps 10.100000
forwardEps 12.181260

RMD's current ratio being 3.06 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that RMD can meet its financial obligations with ease.
ResMed Inc.'s Forward PE is at a healthy level, indicating that the stock price is well-positioned relative to its earnings. With the stock not being overvalued, there remains room for future growth, suggesting a balanced opportunity for investors seeking potential upside.
ResMed Inc.'s low Debt-to-Equity ratio reflects that the company isn't heavily reliant on debt, reducing financial risk. This conservative approach suggests ResMed Inc. maintains a stable financial foundation, with greater flexibility to manage future growth or challenges without over-leverage concerns.
With both earnings and revenue growth showing positive trends, RMD is expected to expand its business. This signals a healthy financial trajectory, suggesting that the company is positioned for continued growth and increasing profitability.
RMD's positive gross and operating margins indicate a profitable and efficient business model. These metrics highlight the company's ability to generate income while controlling operational costs, reflecting strong financial performance.
RMD's forward EPS being higher than its trailing EPS points to expected growth in profitability. This suggests that the company is projected to perform better in the current financial year, with higher earnings forecasted compared to the previous year.

Price projections:

Price projections for RMD
Price projections for RMD

ResMed Inc.'s current price shows alignment with projections, offering no clear risks or opportunities. This neutral stance indicates a stable market environment, where investors may prefer to maintain their positions until more compelling information surfaces.

Insider Transactions:

Insider Transactions for RMD
Insider Transactions for RMD


42 sales transactions of ResMed Inc. were conducted, with market price at 250.1702390398298.No sell transactions were completed during the period under review.With more buys than sells around RMD's current price, there seems to be increased confidence among investors. This shift may indicate a favorable outlook, as the buying behavior suggests optimism for the stock's future growth or resilience.

Recommendation changes over time:

Recommendations trend for RMD
Recommendations trend for RMD


RMD has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as RMD is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.